Dexcom, Inc.'s (NASDAQ:DXCM) fourth-quarter revenue rose 8% year-over-year to $1.114 billion, beating the analyst consensus ...

Dexcom stock stock recovered Friday after the diabetes devices maker missed fourth-quarter profit expectations.

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an ...

Sales: The California-based device maker is pinning its hopes on Stelo, its recently launched device for adults aged 18 and ...

San Diego, California-based DexCom, Inc. (DXCM) is a medical device company that focuses on the design, development, and ...

NSYNC’s Lance Bass shares his journey with type 1.5 diabetes, also known as latent autoimmune diabetes in adults (LADA). The ...

Glucose Market Technological advancements and rising awareness in diabetes management are driving growth in the glucose market, enhancing a ...

Adults with insulin-treated type 2 diabetes had a significant HbA1c decline at 13 weeks with use of the Omnipod 5 automated ...

Much progress has been made in diabetes technology over the past decade. Continuous glucose monitoring has achieved high accuracy and reliability, resulting ...

Stifel Nicolaus analyst Mathew Blackman reiterated a Buy rating on Dexcom (DXCM – Research Report) today and set a price target of $100.00. The ...

Canaccord analyst William Plovanic raised the firm’s price target on DexCom (DXCM) to $103 from $99 and keeps a Buy rating on the shares. The ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...